GlassScriptPhysician profile
Cherry Mae Endo
NPI 1831634559
$1,211.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $522 · 2022: $689.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $258.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.67 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $95.67 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $87.38 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $86.56 | 2021-2022 | |
| Lilly USA, LLC | $58.17 | 2021 | |
| Calliditas Therapeutics US INC. | $53.98 | 2022 | |
| Opko Pharmaceuticals, LLC | $42.19 | 2021-2022 | |
| Abbvie INC. | $35.57 | 2021 | |
| Amarin Pharma, INC. | $34.74 | 2021 | |
| Amgen INC. | $28.80 | 2021 | |
| Mallinckrodt Hospital Products INC. | $28.21 | 2022 | |
| Horizon Therapeutics Plc | $17.03 | 2021 | |
| Fresenius USA Marketing, INC. | $13.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Endo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.